Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Regulatory T cell modulation by CBP/EP300 bromodomain inhibition [ChIP-seq]

ABSTRACT: Genome-wide chromatin H3K27ac, H3K18ac and H3K4me3 occupancy changes in response to CBP inhibitor treatment in Treg cells using ChIP sequencing (ChIP-seq).

ORGANISM(S): Homo sapiens

PROVIDER: GSE70708 | GEO | 2016/04/06

SECONDARY ACCESSION(S): PRJNA289405

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Regulatory T cell modulation by CBP/EP300 bromodomain inhibition [ChIP-seq]

Project description:Genome-wide chromatin H3K27ac, H3K18ac and H3K4me3 occupancy changes in response to CBP inhibitor treatment in Treg cells using ChIP sequencing (ChIP-seq). Expression profiling by ChIP-seq of Treg cells treated with DMSO or CBP inhibitor

2016-04-06 | E-GEOD-70708 | biostudies-arrayexpress

Regulatory T cell modulation by CBP/EP300 bromodomain inhibition [array]

Project description:Genome-wide gene expression changes in response to CBP inhibitor treatment in Treg cells using microarray. Expression profiling by microarray of Treg cells treated with DMSO or CBP inhibitor, and Th0 cells

2016-07-06 | E-GEOD-66596 | biostudies-arrayexpress

Regulatory T cell modulation by CBP/EP300 bromodomain inhibition [RNA-seq]

Project description:Genome-wide gene expression changes in response to CBP inhibitor treatment in Treg cells using RNA sequencing (RNA-seq). Expression profiling by RNA-seq of Treg cells treated with DMSO or CBP inhibitor

2016-04-06 | E-GEOD-70620 | biostudies-arrayexpress

Regulatory T cell modulation by CBP/EP300 bromodomain inhibition [array]

Project description:Genome-wide gene expression changes in response to CBP inhibitor treatment in Treg cells using microarray.

2016-07-06 | GSE66596 | GEO

Regulatory T cell modulation by CBP/EP300 bromodomain inhibition [RNA-seq]

Project description:Genome-wide gene expression changes in response to CBP inhibitor treatment in Treg cells using RNA sequencing (RNA-seq).

2016-04-06 | GSE70620 | GEO

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma (ChIP-Seq)

Project description:Pharmacological inhibition of chromatin co-regulatory factors represents a clinically validated strategy to modulate oncogenic signaling through selective attenuation of gene expression. Here, we demonstrate that CBP/EP300 bromodomain inhibition preferentially abrogates the viability of multiple myeloma cell lines. Phenotypic effects are preceded by the direct transcriptional suppression of the lymphocyte-specific transcription factor IRF4 and the subsequent down-regulation of the IRF4 transcriptional program. Ectopic expression of IRF4 antagonizes the phenotypic effects of CBP/EP300 bromodomain inhibition and prevents the suppression of the IRF4 target c-MYC. These findings suggest that CBP/EP300 bromodomain inhibition represents a viable therapeutic strategy for targeting multiple myeloma and other lymphoid malignancies dependent on the IRF4 network. A total of 13 ChIP-seq samples were sequenced. Samples were treated with control (DMSO) or test compound (2.5 uM SGC-CBP30 or 0.25uM CPI267203) for 6 hours. Signal from input samples was included to subtract background signal from each ChIP-seq sample. Antibodies used were against p300, H3K18ac, H3K27ac, or BRD4.

2016-01-05 | E-GEOD-71909 | biostudies-arrayexpress

Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.

Project description:Covalent modification of histones is a fundamental mechanism of regulated gene expression in eukaryotes, and interpretation of histone modifications is an essential feature of epigenetic control. Bromodomains are specialized binding modules that interact with acetylated histones, linking chromatin recognition to gene transcription. Because of their ability to function in a domain-specific fashion, selective disruption of bromodomain:acetylated histone interactions with chemical probes serves as a powerful means for understanding biological processes regulated by these chromatin adaptors. Here we describe the discovery and characterization of potent and selective small molecule inhibitors for the bromodomains of CREBBP/EP300 that engage their target in cellular assays. We use these tools to demonstrate a critical role for CREBBP/EP300 bromodomains in regulatory T cell biology. Because regulatory T cell recruitment to tumors is a major mechanism of immune evasion by cancer cells, our data highlight the importance of CREBBP/EP300 bromodomain inhibition as a novel, small molecule-based approach for cancer immunotherapy.

| S-EPMC4933219 | biostudies-literature

Regulatory T cell modulation by CBP/EP300 bromodomain inhibition

Project description:Regulatory T cell modulation by CBP/EP300 bromodomain inhibition

| PRJNA289403 | ENA

Bromodomain inhibition of the co-activators CBP/EP300 facilitates reprogramming (ATAC-seq)

Project description:Silencing of the somatic cell-type specific gene expression programs is a critical yet poorly understood step in nuclear reprogramming. To uncover chromatin-related pathways important for maintaining cell identity, we carried out a reprogramming screen using inhibitors of chromatin factors. Here we identify two independent acetyl-lysine competitive inhibitors targeting the bromodomains of coactivators EP300 and CBP as potent enhancers of reprogramming. EP300/CBP bromodomain inhibition is critical during early stages of reprogramming, significantly accelerates the emergence of iPSCs and, when combined with Dot1L inhibition, enables efficient derivation of human iPSCs with Oct4 and Sox2 alone. In contrast, complete inhibition of catalytic acetyl-transferase activity of EP300/CBP prevents reprogramming. Genome-wide expression analyses indicate that EP300/CBP bromodomain inhibition diminishes the expression of somatic-specific genes without affecting the induction of pluripotency regulators. Through expression analyses, we identify the master mesenchymal transcription factor PRRX1 as a functionally important target in reprogramming that is downregulated upon EP300/CBP bromodomain inhibition. Collectively, our data uncover a role for bromodomain-mediated interactions of EP300/CBP in sustaining cell type specific gene expression programs and maintaining somatic cell identity

2019-02-14 | GSE118218 | GEO

Bromodomain inhibition of the co-activators CBP/EP300 facilitates reprogramming (ChIP-seq II)

2019-02-14 | GSE124581 | GEO